• PP 1: From Radiopathomics to Src Signaling

  2026-08-18

  Radiopathomics can identify clinically meaningful immune and treatment-response patterns, but mechanistic perturbation is needed to determine whether Src-family signaling contributes to those phenotypes. This article presents PP 1 as a selective research tool for connecting multimodal gastric cancer signatures with Lck, Fyn, Lyn, and RET-related biology while preserving translational rigor.

• SP2509 for LSD1-Directed AML Research

  2026-08-17

  SP2509 connects nanomolar LSD1 inhibition with practical assays for chromatin remodeling, apoptosis, and differentiation in acute myeloid leukemia research. This guide emphasizes solvent handling, orthogonal validation, clonogenic readouts, and careful interpretation of cross-cancer epigenetic evidence.

• Trelagliptin Succinate: A Mechanism-First Guide

  2026-08-16

  Trelagliptin succinate is more than a long-acting DPP-4 inhibitor for glucose studies. This mechanism-first guide connects incretin pharmacology with causal AMPK/SOX-9 evidence, helping researchers choose assays, concentrations, controls, and interpretation boundaries.

• Elobixibat Hydrate: From IBAT Biology to Translation

  2026-08-15

  A translational perspective on how Elobixibat hydrate converts bile acid trafficking into a gut-focused therapeutic strategy, with practical guidance for mechanism validation, clinical positioning, and reproducible research workflows.

• Tiamulin (Thiamutilin): Reliable Cell Assays

  2026-08-15

  Learn how Tiamulin (Thiamutilin), SKU BA1083, can be integrated into reproducible cell viability, proliferation, cytotoxicity, antibacterial, and inflammation workflows. This scenario-based guide covers mechanism, solvent compatibility, concentration design, interpretation, and practical vendor selection.

• Protease Inhibitor Cocktail for OXPHOS Assays

  2026-08-14

  Protect labile proteins during OXPHOS, Western blot, co-IP, and tissue extraction workflows with a broad-spectrum, EDTA-free formulation. This guide connects practical sample-preservation choices to the dual-genome OXPHOS mechanism reported for LRPPRC inhibition and dasatinib.

• Mitoxantrone HCl: Topoisomerase II Research Guide

  2026-08-14

  Mitoxantrone HCl is a DNA topoisomerase II inhibitor used to model DNA damage, apoptosis, immune modulation, and tumor-cell viability. Recent evidence also supports a distinct ERα DBD–LBD interface mechanism, but this finding should not be treated as proof that every salt-form assay is ERα-mediated.

• SLC2A5 Fructose Metabolism in PCNSL

  2026-08-13

  This Advanced Science study uses single-cell RNA and B-cell receptor profiling to connect the hypoxic, glucose-deprived PCNSL microenvironment with SLC2A5-mediated fructose metabolism in lymphoma cells and tumor-supportive macrophages. Genetic and pharmacological inhibition of SLC2A5 suppressed lymphoma growth in functional models, identifying a potential metabolic vulnerability while highlighting the need for clinical validation.

• Arrb2, 6-ketoLCA, and Liver IRI

  2026-08-13

  The reference study identifies a hepatocyte-specific Arrb2–6-ketoLCA axis that promotes M2 macrophage polarization and limits hepatic ischemia–reperfusion injury. By combining clinical samples, mouse injury models, hepatocyte/macrophage experiments, and metabolite analysis, it provides a mechanistic framework for studying metabolic communication during liver transplantation-related injury.

• FAPα-Sensitive Nanoparticles for Urinary Tumor Diagnosis

  2026-08-12

  Feng and colleagues developed magnetic iron oxide nanoparticles carrying a substrate–reporter peptide that is cleaved by fibroblast activation protein α (FAPα) in tumor tissue and produces a urinary signal. In an esophageal squamous cell carcinoma xenograft model, the platform combined tumor localization, enzymatic activation, and ELISA-based urine analysis, achieving an area under the ROC curve of 1.0 in the reported dataset.

• Modified Ethanol Injection for mRNA Lipoplexes

  2026-08-12

  Tang and colleagues evaluated a modified ethanol injection method for preparing mRNA lipoplexes without the specialized equipment commonly associated with microfluidic mixing. Screening 18 lipid combinations identified DC-1-16 or TC-1-12 formulations with DOPE and PEG-Chol as strong candidates for cellular expression, while the DC-1-16 formulation also supported protein expression in mouse lungs and spleen and induced antigen-specific IgG1 responses.

• Amplex Red Workflows for Reliable H2O2 Detection

  2026-08-11

  Amplex Red converts low-abundance hydrogen peroxide into a measurable resorufin signal for enzyme, mitochondrial, and cell-based studies. This practical guide combines assay setup with matrix controls that address a major interpretive risk: carboxylesterase-driven probe conversion independent of hydrogen peroxide.

• ROS-Responsive Nanoparticles Drive Cuproptosis

  2026-08-10

  The reference study developed ROS-responsive nanoparticles that co-deliver elesclomol and copper, enabling tumor-selective cargo release, cuproptosis, and immune remodeling. Its combination with αPD-L1 provides a mechanistically integrated strategy for converting copper-dependent cancer-cell killing into enhanced immunotherapy.

• Dynamic mRNA Delivery by Lipid Nanoparticles

  2026-08-09

  The reference study establishes a live-imaging framework that separates lipid nanoparticle biodistribution, mRNA release, and protein expression in vivo. By combining DiR-labeled nanoparticles, Cy5-labeled luciferase mRNA, FRET analysis, fluorescence imaging, bioluminescence imaging, and lipid metabolism measurements, it shows how administration route and ionizable-lipid degradability shape delivery outcomes.

• BCECF-AM for Intracellular pH Measurement

  2026-08-08

  BCECF-AM converts esterase activity inside living cells into a ratiometric readout of intracellular pH, making it useful for dynamic stress, secretion, and autophagy workflows. Applied to the Arabidopsis SINAT–V-ATPase question, it complements—not replaces—direct assays of vacuolar acidification and autophagic vesicle turnover.

457 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page